60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
60 Degrees Pharmaceuticals signed a sponsored research agreement with the University of Southern Mississippi to evaluate castanospermine in nonclinical models of alpha-gal syndrome. The company underwrites the research and retains an option to commercialize any resulting IP, with a possible botanical approval pathway ahead of any Rx development program. There are no FDA-approved treatments for AGS, so the program addresses an unmet need, though it remains at a preclinical stage.
Key figures
- Drug Name
- castanospermine
- Active clinical trials
- 3
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.